Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Nonclinical evaluation of APL-4098, a novel GCN2 kinase inhibitor, reveals potent anti-leukemic effects through mitochondrial stress induction and synergy with venetoclax, targeting AML blasts and LSCs

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKevin Blighe

Discussion

Loading...

Member takes

Overview

Nonclinical evaluation reveals APL-4098 reduces LSCs and enhances venetoclax synergy in leukemia models, highlighting promising therapeutic potential.

Key Points

  • APL-4098 reveals potent anti-leukemic effects through synergistic action with venetoclax, particularly on LSCs.
  • Significant tumor growth inhibition was observed with APL-4098, achieving up to 98.7% reduction in models.
  • Biochemical assays confirmed GCN2 inhibition with a Ki of 4.4 nM and demonstrated efficacy on AML patient samples.
  • Combining APL-4098 with venetoclax highlights a promising strategy for targeting acute myeloid leukemia.

Cite This Study

Kevin Blighe (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce2https://doi.org/10.1182/blood-2025-1503
View Full Paper
Ask AI
Bookmark
Share